Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

• Katie Erdos,
• Aya Alshareef,
• Richard T. Silver,
• Joseph M. Scandura,
• Ghaith Abu-Zeinah

Affiliations

Katie Erdos

Richard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY

Aya Alshareef

Weill Cornell Medicine-Qatar, Doha, Qatar

Richard T. Silver

Richard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY

Joseph M. Scandura

Richard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY

Ghaith Abu-Zeinah

Richard T. Silver, M.D. Myeloproliferative Neoplasm Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY; Correspondence: Ghaith Abu-Zeinah, Division of Hematology and Medical Oncology, Weill Cornell Medicine, 1300 York Ave, Box 113, New York, NY 10065;